GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

DelveInsight's 'Severe Asthma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline severe asthma ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated ...

The big pharma company GlaxoSmithKline will inject up to $800 million into its manufacturing site in Marietta, Pennsylvania, ...

the full trial data paints a more down-to-earth reality – with some disappointing real-world outcomes for GSK. Data published by the New England Journal of Medicine (NEJM) on Sunday shows the ...

London-based GSK is crossing the pond ... with Boston scientists. The Big Pharma is joining forces with researchers from the Center for Regenerative Medicine (CReM) at Boston University and ...

CG-TIC will be co-led by Nicolas Wisniacki, VP, Clinical Research Head, GSK, and David Thomas, Professor of Renal Medicine and principal investigator ... Europe's leading industry-sponsored portal for ...

GSK cut its full-year vaccine sales outlook after key shots for respiratory syncytial virus and shingles missed expectations ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK has lowered its vaccine sales forecast for the year because of weak demand for its new respiratory ...